Replimune Group, Inc. (NASDAQ:REPL – Get Rating) CEO Philip Astley-Sparke sold 9,632 shares of the firm’s stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $14.59, for a total transaction of $140,530.88. Following the completion of the transaction, the chief executive officer now owns 1,401,080 shares in the company, valued at approximately $20,441,757.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of REPL stock opened at $14.23 on Thursday. The stock has a 50 day moving average of $16.79 and a two-hundred day moving average of $21.90. The company has a current ratio of 23.39, a quick ratio of 23.39 and a debt-to-equity ratio of 0.06. Replimune Group, Inc. has a 12 month low of $13.05 and a 12 month high of $40.22. The company has a market capitalization of $671.80 million, a P/E ratio of -6.87 and a beta of 2.29.
A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in shares of Replimune Group by 2.3% during the fourth quarter. BlackRock Inc. now owns 2,137,118 shares of the company’s stock worth $57,915,000 after purchasing an additional 48,263 shares during the period. State Street Corp increased its position in Replimune Group by 36.6% during the 1st quarter. State Street Corp now owns 1,712,037 shares of the company’s stock worth $29,070,000 after buying an additional 458,420 shares during the period. Vanguard Group Inc. increased its position in shares of Replimune Group by 5.3% in the first quarter. Vanguard Group Inc. now owns 1,625,758 shares of the company’s stock worth $27,606,000 after purchasing an additional 81,845 shares during the period. Emerald Advisers LLC grew its position in Replimune Group by 14.6% in the first quarter. Emerald Advisers LLC now owns 1,134,012 shares of the company’s stock valued at $19,256,000 after acquiring an additional 144,054 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust increased its position in Replimune Group by 5.8% in the 4th quarter. Emerald Mutual Fund Advisers Trust now owns 1,075,464 shares of the company’s stock valued at $29,145,000 after acquiring an additional 58,527 shares during the period. 75.42% of the stock is owned by hedge funds and other institutional investors.
About Replimune Group (Get Rating)
Replimune Group, Inc, a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma.
- Get a free copy of the StockNews.com research report on Replimune Group (REPL)
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Dynatrace: Fundamentals are Positive While Being Punished
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.